« Return to News | Ethics/Regulatory

FDA approves Whooping Cough vaccine

Monday, July 11, 2011 12:24 PM

The FDA has approved GlaxoSmithKline’s BOOSTRIXR [Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap)] for use in adults 65 years of age and older for active booster immunization against tetanus, diphtheria and pertussis (whooping cough). This approval makes BOOSTRIX the first Tdap vaccine approved for use in this age group.

BOOSTRIX is now approved for use as a single dose in individuals 10 years of age and older—the broadest age range for any Tdap vaccine.

The approval of BOOSTRIX for use in adults 65 years of age and older was based on two clinical trials in which more than 1,100 U.S. subjects received BOOSTRIX

"Although many people may have been vaccinated against whooping cough as children, immunity can wear off over time.  Adults, including those aged 65 and older, should speak with their healthcare providers to make sure their vaccinations are up to date and to discuss the Centers for Disease Control and Prevention's (CDC) recommendations for preventing tetanus, diphtheria and pertussis,” said Leonard Friedland, GSK’s vice president, clinical and medical affairs for North America. 

Whooping cough is one of the most commonly occurring vaccine-preventable diseases in the U.S.

In 2010, California declared a whooping cough epidemic. Michigan, Ohio, New York and Pennsylvania also reported increases in cases in 2010 compared to 2009.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.